CCTG Clinical Trials
Public Trial Select
Member Trial Select
TAILORx | MAC12 trial showed no benefit from chemotherapy for many women with breast cancerClinical trials are not always about finding a new drug that works but sometimes challenge current standards of care that may help spare patients unnecessary treatment. More >> |
Recently Activated Trials
Member Links
CCTG’s MA.39 trial receives green light from funding bodiesOne of the most promising advances in cancer treatment is the use of biological markers or biomarkers to identify the therapies a particular cancer may or may not respond to. More >> |
Planned Trials
Committees Select
Group newsletter: CCTG Connection
February 19, 2020
CCTG awarded $1,303,560 in the Fall 2019 CIHR Project GrantPublished: February 19, 2020Category: News  CCTG has been awarded $1,303,560 from the Fall 2019 CIHR Project Grant competition, a program that helps advance health-related research. The funds will support the Canadian contribution to the ME15 international trial, investigating use of smaller surgical margins to reduce the extent of surgery in Stage 2 melanoma patient - Larger margins result in disfigurement, wound discomfort, and time away from work and, if positive, will change practice in Canada and around the world. Read More |
February 05, 2020
Seeking nominations for the 2020 CCTG Recognition AwardsPublished: February 05, 2020Category: Group updates  The Canadian Cancer Trials Group is seeking nominations for the 2020 Recognition Awards honouring individuals who have contributed significantly to the mission and activities of the Canadian Cancer Trials Group. Read More |
 The 2020 CCTG Annual Spring Meeting of Participants will be here before you know it! Make sure that you save the date: May 1 - 3, Chelsea Hotel, Toronto.
|
Clinical Research Associate (CRA) Volunteers Needed for Endpoint & Disease Site Executive Committees!Published: February 05, 2020Category: Group updates  The Canadian Cancer Trials Group is actively seeking CRA representatives from Canadian Member sites to sit on the Genitourinary Disease Site Committee Executives as well as Supportive Care Committee. Read More |
 |
 PR17 - Randomised Phase III Trial of Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer: ENZAMET.
MEC4 - Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma.
IND205 - A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer (CRPC).
|
PR17 (ENZAMET) featured in ASCO's Clinical Cancer Advances 2020Published: February 05, 2020Category: Publications  ENZAMET | CCTG PR17 (NCT02446405) study has been highlighted by the American Society of Clinical Oncology (ASCO) 2020 annual report as a major advance in cancer treatment. The results were first presented at ASCO 2019, the trial demonstrated that hormone therapy with a drug called enzalutamide can improve the survival of some men with advanced, hormone‐sensitive prostate cancer. Read More |
From the Directors Desk: CCTG 2019 a year in reviewPublished: February 05, 2020Category: Office of the Director  As 2020 begins, I wanted to take a moment to reflect on the hard work and accomplishments of our network of researchers and collaborators, both nationally and internationally, over the past year. This year we supported 67 ongoing trials while working with our scientific network to activate 15 new trials of which 10 are being led by CCTG. This includes the IND234 trial that opened three new treatment arms this year—IND234 is the first trial to evaluate a precision medicine approach for patients with advanced prostate cancer using liquid biopsies for genomic testing. Read More |